Back to YC Companies
Nephrogen
Summer 2020
Active
Curative genetic medicines for kidney diseases
5 people View on YC
Nephrogen at a glance
- Y Combinator batch
- Summer 2020
- Status
- Active
- Industry
- Healthcare
- Team size
- 5 people
- Location
- Not recorded
- Website
- Not recorded
Every field above comes from the Y Combinator company record. Nothing is estimated.
About Nephrogen
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
Tags:
Gene Therapy
CRISPR
Biotech